{
    "symbol": "AMGN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-27 20:27:03",
    "content": " The innovative brands that we highlighted in February continued to generate strong volume growth in the first quarter, including Repatha, which was up 49%; Prolia, up 10%; EVENITY, up 59%; and Otezla, up 7% as well as several of our oncology products, which also generated attractive volume growth in the quarter. First, investing in the best innovation, internal and external; second, investing in our business through capital expenditures, including for our new environmentally friendly facilities under construction in Ohio and North Carolina; and third, returning capital to shareholders through growing dividends, including $1.94 per share in the quarter, representing a 10% increase from Q4 2021; and fourth, opportunistic share repurchases, including 24.6 million shares of common stock in the first quarter, which included 23.3 million initial shares received and retired under the accelerated stock buyback agreement. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}